Bioequivalence Study of Linagliptin From Prevaglip 5 mg Tablets(Eva Pharma, Egypt) and Trajenta 5 mg Tablets (Boehringer Ingelheim International GmbH, Germany)

• ClinicalTrials.gov Identifier: NCT02857946
• Recruitment Status: Completed
• First Posted: August 5, 2016
• Last Update Posted: August 5, 2016
• Sponsor: Genuine Research Center, Egypt
• Collaborator: Eva Pharma
• Information provided by (Responsible Party): Genuine Research Center, Egypt

Study Description

Brief Summary:

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Linagliptin from Prevaglip 5 mg tablets(Eva pharma for Pharmaceuticals & Medical Appliances, Egypt) and Trajenta 5 mg tablets(Boehringer Ingelheim International GmbH, Germany) after a single oral dose administration of each to healthy adults under fasting conditions

Condition or disease	Intervention/treatment	Phase
Healthy	Drug: Prevaglip (linagliptin); Drug: Trajenta (linagliptin)	Phase 1

Detailed Description:

Primary Pharmacokinetic Parameters: Cmax, AUC0→t and AUC0→∞ Secondary Pharmacokinetic Parameters: Ke, tmax and t1/2e. ANOVA using 5% significance level for transformed (with the 90% confidence intervals) and untransformed data of Cmax, AUC0→t and AUC0→∞ and for untransformed data of Ke, tmax and t1/2e.

The confidence intervals of logarithmically transformed Test/Reference ratios for Cmax, AUC0→t and AUC0→∞ to be within 80.00-125.00%.

A comprehensive final report will be issued upon the completion of the study.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 24 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Masking: None (Open Label)
• Official Title: Open Label, Randomized, Single Dose, Two-way Crossover Bioequivalence Study of Linagliptin From Prevaglip 5 mg Tablets (Eva Pharma, Egypt) and Trajenta 5 mg Tablets (Boehringer Ingelheim International GmbH, Germany)
• Study Start Date: February 2016
• Actual Primary Completion Date: March 2016
• Actual Study Completion Date: April 2016

Arms and Interventions

Arm	Intervention/treatment
Experimental: A Test; Test drug (Prevaglip) 1 tablet contains 5 mg linagliptin	Drug: Prevaglip (linagliptin); 1 tablet contains 5 mg linagliptin; Other Name: Prevaglip
Active Comparator: B Reference; Reference drug (Trajenta) 1 tablet contains 5 mg linagliptin	Drug: Trajenta (linagliptin); 1 tablet contains 5 mg linagliptin; Other Name: Trajenta

Outcome Measures

Primary Outcome Measures :

1. Maximal measured plasma concentration (Cmax) [ Time Frame: Up to 72 hours post dose in each treatment period ]
   Serial blood samples for determination of study drug will be collected at 0.00, 0.33, 0.66, 1.0, 1.25, 1.5, 1.75, 2.00, 2.5, 3.0, 4, 6, 8, 12, 24, 48 and 72 hours

Secondary Outcome Measures :

1. Time of the maximum plasma concentration (Tmax) [ Time Frame: Up to 72 hours post dose in each treatment period ]
   Serial blood samples for determination of study drug will be collected at 0.00, 0.33, 0.66, 1.0, 1.25, 1.5, 1.75, 2.00, 2.5, 3.0, 4, 6, 8, 12, 24, 48 and 72 hours

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 55 Years (Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

1. Healthy male or female, age 18 to 55 years, inclusive.
2. Body weight within 15% of normal range according to the accepted normal values for body mass index (BMI).
3. Medical demographics without evidence of clinically significant deviation from normal medical condition.
4. Results of clinical laboratory test are within the normal range or with a deviation that is not considered clinically significant by principal investigator.
5. Subject does not have allergy to the drugs under investigation.

Exclusion Criteria:

1. Subjects with known allergy to the products tested.
2. Subjects whose values of BMI were outside the accepted normal ranges.
3. Female subjects who were pregnant, nursing or taking birth control pills.
4. Medical demographics with evidence of clinically significant deviation from normal medical condition.
5. Results of laboratory tests which are clinically significant.
6. Acute infection within one week preceding first study drug administration.
7. History of drug or alcohol abuse.
8. Subject does not agree not to take any prescription or non-prescription drugs within two weeks before first study drug administration and until the end of the study.
9. Subject is on a special diet (for example subject is vegetarian).
10. Subject does not agree not to consume any beverages or foods containing methyl-xanthenes e.g. caffeine (coffee, tea, cola, chocolate etc.) 48 hours prior to the study administration of either study period until donating the last sample in each respective period.
11. Subject does not agree not to consume any beverages or foods containing grapefruit 7 days prior to first study drug administration until the end of the study.
12. Subject has a history of severe diseases which have direct impact on the study.
13. Participation in a bioequivalence study or in a clinical study within the last 6 weeks before first study drug administration.
14. Subject intends to be hospitalized within 3 months after first study drug administration.
15. Subjects who, through completion of this study, would have donated more than 500 ml of blood in 7 days, or 750 ml of blood in 30 days, 1000 ml in 90 days, 1250 ml in 120 days, 1500 ml in 180 days, 2000 ml in 270 days, 2500 ml of blood in 1 year.

Contacts and Locations

Locations

Egypt

Genuine Research Center GRC

Cairo, Egypt, 11757

Sponsors and Collaborators

Genuine Research Center, Egypt

Eva Pharma

Investigators

• Study Director: Ahmed Elshafeey, Ph.D. Pharma; Genuine Research Center

More Information

Additional Information:

Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95) The European Agency for the Evaluation of Medicinal Products (EMEA) May 1997 

Note for Guidance on Clinical Safety Data Management; Definitions And Standards for Expedited Reporting (CPMP/ICH/377/95) The European Agency for the Evaluation of Medicinal Products (EMEA) June 1995. 

International conference of Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonized Tripartite Guideline. Guidelines for Validation of Analytical Procedures: Methodology. November, 1996 

Publications:

Chow SC, Wang H. On sample size calculation in bioequivalence trials. J Pharmacokinet Pharmacodyn. 2001 Apr;28(2):155-69. Erratum in: J Pharmacokinet Pharmacodyn. 2002 Feb;29(1):101..

Diletti E, Hauschke D, Steinijans VW. Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol. 1991 Jan;29(1):1-8.

Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987 Dec;15(6):657-80.

• Responsible Party: Genuine Research Center, Egypt
• ClinicalTrials.gov Identifier: NCT02857946
• Other Study ID Numbers: GRC/1/15/596
• First Posted: August 5, 2016
• Last Update Posted: August 5, 2016
• Last Verified: August 2016

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

Additional relevant MeSH terms:

Linagliptin; Hypoglycemic Agents; Physiological Effects of Drugs; Incretins; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Dipeptidyl-Peptidase IV Inhibitors; Protease Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action